[196+ Pages Report] The global ADME toxicology testing market is set for rapid growth over the forecast period. In terms of revenue, the global ADME toxicology testing market accounted for USD 5.4 Billion in 2020 and is anticipated to reach around USD 11.4 Billion by 2026, growing at a CAGR of 11.4%.
ADME toxicology testing is primarily used to perform pharmacological, chemical, and genetic experiments and tests that assist in the drug development process, from drug formulation to drug trials and other drug interactions. Various liquid-handling instruments, control software, and other detectors are used in this method to quickly distinguish genetic interactions, active compounds, and other biomolecular interactions.
The growth of the ADME toxicology testing market can be attributed to the growing number of drug designs and the increasing demand from biotechnology and pharmaceutical companies due to the reduced cost of various tests that are required during drug development. Also, factors such as reduced time required for commercialization of drug lower number of failures during drug development are also expected to drive the market growth. To avoid late-stage failure and ensure systematic assessment, ADME toxicology monitoring is now performed during the drug design and production process. To meet regulatory requirements, most businesses use GLP and non-GLP testing methods. To achieve consistency and authenticity of collected and processed data, regulatory bodies are being urged to define stricter quality control requirements. However, the market's growth is expected to be hampered by a shortage of effective software to manage liquid handling systems and automated robotic arms. Regulatory reforms by regulatory bodies such as the FDA in the United States are expected to have an effect on the industry and the manner in which technologies are pursued. For example, few FDA departments have requested that businesses do ADME toxicology tests on animals in the same disease state as humans, in order to draw a straight distinction between real-time outcomes from the near condition and results from normal animals. In addition, owing to the widespread outbreak of coronavirus disease (COVID-19) and the absence of an appropriate vaccine or cure, ADME toxicology testing is being used to measure the efficacy of existing medications as a potential treatment, which is boosting market development. Over the forecast period, the global ADME toxicology testing industry is expected to expand at a rapid pace.
The global ADME toxicology testing market is divided into its technology, application, method, end-user, and regions. Based on technology, the global market is divided into molecular imaging, cell culture, OMICS technology, and high throughput. The cell culture category in technology segmentation dominated the technology segmentation in 2019 with market share of around 40% and is expected to continue its dominance in upcoming years. The dominance of the cell culture category can be attributed to the emergence of assays using the fluorometric imaging plate reader (FLIPR) and their capability to test small volumes. Ultra ADME toxicology testing is the most recent innovation in the industry, resulting in higher productivity in less time. Many businesses are in the process of transitioning from conventional 2D to 3D cell cultures. Based on the application, the global market is divided into renal toxicity, neurotoxicity, systemic toxicity, hepatotoxicity, and other toxicities. The systemic toxicity category in application segmentation dominated the application segmentation in 2019 with market share of around 70% and is expected to continue its dominance in upcoming years. This can be attributed to the popularity of systemic circulation as one of the most chosen methods for drug distribution. The renal toxicity category is expected to grow at a healthy rate in the forecast period due to new studies and active researches that are being presently carried out in the industry hence registering a growth rate more than systemic toxicity. Based on the method, the market is divided into biochemical assay, ex-vivo, cellular assay, and in-silica. Based on the end-user, the market is divided into food industry, pharmaceutical industry, animal industry, cosmetics & household products, and others. Geographically, the global market is divided into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.
The North America region dominated the global ADME toxicology testing market in 2019 with a market share of around 45% and is anticipated to continue its dominance in the forecast period. The dominance of the North America region can be attributed to the current as well as upcoming technological advancements in the new drug molecule development especially in the drug discovery with the help of cell cultures. In addition, one of the major industry developments is the Food and Drug Administration's (FDA) introduction of multiple guidance documents that offer instruction on ADME properties when assessing the efficacy and safety of a drug candidate. Apart from that, software that calculates ADME automatically is gaining popularity as an alternative to traditional in vivo and in vitro experiments.
The Asia Pacific region is anticipated to grow at a significant rate in the upcoming years attributed to the adoption of new technologies by countries such as Japan, India, China, and South Korea in order to improve the medical standards. Also, the increasing efforts by countries such as Japan and China for developing newer pharmaceutical molecules are expected to drive the growth of the region in the forecast period.
Report Attribute |
Details |
Market Size in 2020 |
USD 5.4 Billion |
Projected Market Size in 2026 |
USD 11.4 Billion |
Growth Rate |
CAGR 11.4% |
Base Year |
2020 |
Forecast Years |
2021–2026 |
Key Market Players |
Thermo Fisher Scientific Inc., Promega Corporation, Beckman Coulter, Inc., (Danaher), Albany Molecular Research Inc., Eurofins Scientific SE, Life Technologies Corporation, Quintiles, Agilent Technologies, Accelrys, Inc., (Dassault Systemes BIOVIA), Catalent, Covance, Inc. (LabCorp), Charles River Laboratories International, Inc., General Electric Company (Healthcare), and Miltenyi Biotec among others. |
Key Segment |
By Technology, By Application, By Method, End-User, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Some of the key players in the market are:
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors